NEWPORT BEACH, CA / ACCESSWIRE / October 26, 2023 / Vivera Pharmaceuticals, Inc. is pleased to announce the litigation involving Pedram Salimpour has been dismissed, leaving Salimpour with nothing by way of settlement.
NEWPORT BEACH, Calif., Feb. 14, 2023 /PRNewswire/ -- Vivera welcomes Mr. Dennis Moore as its Regulatory and Compliance Advisor. Mr. Moore will guide Vivera through the regulatory pathway for ZICOH, the Company's intelligent, dose-controlled prescription medication delivery system.
NEWPORT BEACH, Calif. , Jan. 5, 2023 /PRNewswire/ -- With its exclusive global license to the TABMELT technology for pharmaceutical use, Vivera is pleased to announce the expansion of the Company's international presence with the recent grant of the TABMELT patent in Israel. The newly granted TABMELT patent from the Israel Patent Office (ILPO) will enable the Company to expand the sublingual drug delivery system's global opportunities and reach.
NEWPORT BEACH, Calif., Dec. 7, 2022 /PRNewswire/ -- Veteran publicist Amanda Whitcroft joins Vivera's team as Director of Public Relations. In her new role, she will utilize her experience and expansive network to generate a consistent and strategic corporate and media communications strategy while maximizing opportunities to feature the Company's vision, milestones, and accomplishments.
Vivera, an innovative, science-driven pharmaceutical company, announced the expansion of its exclusive global license to the novel Tabmelt platform for pharmaceutical use in Israel. This latest patent allowance by the Israel Patent Office (ILPO) follows international Tabmelt patent grants in Canada, Russia, Australia, and the United Kingdom.
NEWPORT BEACH, Calif., Oct. 25, 2022 /PRNewswire/ -- Vivera is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. patent allowance for the Company's Speech Fluency Evaluation and Feedback method and device.
NEWPORT BEACH, Calif., Oct. 20, 2022 /PRNewswire/ -- Vivera is pleased to welcome Lea Ramirez to the Company's Advisory Board. Ms. Ramirez joins Vivera's Advisory Board to assist with healthcare strategy and planning as the Company works on its shorter and longer-term commercialization strategies and projects.
NEWPORT BEACH, Calif., Oct. 12, 2022 /PRNewswire/ -- Vivera is pleased to welcome Dr. Geetha Rao to the Company's Advisory Board as its Regulatory Advisor. Dr. Rao will guide Vivera through its regulatory pathway for its medical device and technology products, ZICOH and MDZone.
The Securities and Exchange Commission (SEC) has charged a sublingual drug delivery company and its CEO with an alleged offering fraud that raised $6.6 million. The company, Vivera Pharmaceuticals, hit back against what it says are “meritless allegations” made in a “politically motivated” litigation filing.